Plex Pharmaceuticals Inc., of San Diego, said it received a $670,865 grant from the Michael J. Fox Foundation for Parkinson's Research through its Therapeutic Pipeline Program. Under that funding, Plex will employ its fragment-based screening technology combined with structure-based drug design to discover and develop brain-permeable drug candidates targeting two promising Parkinson's disease-modifying proteins, FK506 binding protein 12 (FKBP12) and FKBP52, which accelerate and promote the aggregation of alpha-synuclein, a hallmark of Parkinson's pathology.